{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:11:26Z","timestamp":1776312686303,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.clindermatol.2019.10.006","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T12:12:05Z","timestamp":1571919125000},"page":"208-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug eruptions associated with tumor therapy: Great imitators"],"prefix":"10.1016","volume":"38","author":[{"given":"Catherine","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah","family":"Au","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2019.10.006_bb0005","series-title":"Litt\u2019s Drug Eruption and Reaction Manual","first-page":"219","article-title":"Methotrexate","author":"Litt","year":"2015"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0190-9622(91)70073-B","article-title":"Chemotherapy-induced acral erythema","volume":"24","author":"Baack","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome: incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1345\/aph.18281","article-title":"Acral erythema associated with high-dose methotrexate infusion","volume":"33","author":"Ikeda","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4103\/0378-6323.29341","article-title":"Bullous variant of acral erythema due to methotrexate","volume":"72","author":"Kuruvila","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/08998280.2018.1463039","article-title":"Cutaneous toxicity of oral low-dose methotrexate","volume":"31","author":"Jalandhara","year":"2018","journal-title":"Proc Bayl Univ Med Cent"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1525-1470.2007.00513.x","article-title":"Acral erythema with oral methotrexate in a child","volume":"24","author":"Varela","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0040","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-111-8-688","article-title":"Pyridoxine for the palmar-plantar erythrodysesthesia syndrome","volume":"111","author":"Vukelja","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00043426-200203000-00018","article-title":"Bullous acral erythema secondary to high-dose methotrexate","volume":"24","author":"Morrell","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/0003-4819-97-5-783","volume":"97","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0055","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2147\/TCRM.S1155","article-title":"Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides","volume":"4","author":"Breneman","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2133.1970.tb02194.x","article-title":"Intermittent high dose oral methotrexate therapy in psoriasis","volume":"82","author":"Baker","year":"1970","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0065","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0190-9622(84)70259-3","article-title":"Two patterns of skin ulceration induced by methotrexate in patients with psoriasis","volume":"11","author":"Lawrence","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0190-9622(83)70079-4","article-title":"Methotrexate-induced necrolysis","volume":"8","author":"Reed","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-4362.1988.tb02342.x","article-title":"Erosion of psoriatic plaques after chronic methotrexate administration","volume":"27","author":"Kaplan","year":"1988","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0080","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0190-9622(96)90097-3","article-title":"Erosion of psoriatic plaques: an early sign of methotrexate toxicity","volume":"35","author":"Pearce","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0085","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0190-9622(97)70029-X","article-title":"Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis","volume":"36","author":"Primka","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1067\/mjd.2003.388","article-title":"Cutaneous ulceration caused by methotrexate","volume":"49","author":"Kazlow","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0095","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/2229-5178.156442","article-title":"Acute methotrexate toxicity presenting as ulcers in plaques of psoriasis vulgaris","volume":"6","author":"Bhatnagar","year":"2015","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1345\/aph.17300","article-title":"Cutaneous ulceration: an unusual sign of methotrexate toxicity\u2014first report in a patient without psoriasis","volume":"32","author":"Ben-Amitai","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0105","first-page":"1668","article-title":"Methotrexate-induced skin detachment","volume":"21","author":"Aractingi","year":"1992","journal-title":"Presse Med"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0110","first-page":"88","article-title":"Methotrexate-induced erythema multiforme","volume":"10","author":"Kim","year":"2013","journal-title":"Commun Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0090-8258(89)90531-3","article-title":"Methotrexate-induced erythema multiforme","volume":"33","author":"Taylor","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0120","first-page":"377","article-title":"Methotrexate-induced erythema multiforme: a case report and review of the literature","volume":"30","author":"Omoregie","year":"2011","journal-title":"West Afr J Med"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5376476","article-title":"Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies","volume":"2018","author":"Ng","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0130","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.3390\/ijms15033403","article-title":"Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells","volume":"25","author":"Swift","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0135","first-page":"203","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I Conventional chemotherapeutic drugs","volume":"71","author":"Reyes-Habito","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ajd.12406","article-title":"Cyclophosphamide in dermatology","volume":"58","author":"Kim","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0733-8635(05)70006-1","article-title":"Immunosuppressive agents in dermatology: an update","volume":"16","author":"Dutz","year":"1998","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0150","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.kint.2016.08.005","article-title":"Melanonychia following cyclophosphamide therapy","volume":"90","author":"Gupta","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11096-013-9756-1","article-title":"Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation","volume":"35","author":"Youssef","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0160","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bmt.1702016","article-title":"Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide","volume":"24","author":"Worth","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000073355","article-title":"Dose finding of ifosfamide administered with a chronic two-week continuous infusion","volume":"65","author":"Cartei","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0170","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0175","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3816\/CGC.2004.n.020","article-title":"Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer","volume":"3","author":"Berry","year":"2004","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0185","doi-asserted-by":"crossref","first-page":"207084","DOI":"10.1155\/2010\/207084","article-title":"Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review","volume":"2010","author":"Makrilia","year":"2010","journal-title":"Met Based Drugs"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0190","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0195","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.7314\/APJCP.2016.17.4.1617","article-title":"Three weekly versus weekly cisplatin as radiosensitizer in head and neck cancer: a decision dilemma","volume":"17","author":"Negi","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0200","first-page":"3241","article-title":"A phase II study of HMB\/Arg\/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer","volume":"26","author":"Yokota","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0205","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/TCRM.S3348","article-title":"Pegylated liposomal doxorubicin in the management of ovarian cancer","volume":"6","author":"Ferrandina","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/07357900802392667","article-title":"Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin","volume":"27","author":"Gzell","year":"2009","journal-title":"Cancer Investig"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00128071-200607010-00005","article-title":"Cutaneous reactions to chemotherapy and their management","volume":"7","author":"Wyatt","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0220","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1200\/JCO.2013.48.7470","article-title":"Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management","volume":"32","author":"Najem","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0225","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","article-title":"The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials","volume":"18","author":"Gibson","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0230","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.3892\/ol.2016.5309","article-title":"Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: a case report and review of the literature","volume":"12","author":"Kubicka-Wo\u0142kowska","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0235","first-page":"566","article-title":"Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome","volume":"18","author":"Mangana","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0240","first-page":"72","article-title":"An illustrated case of doxorubicin-induced radiation recall dermatitis and a review of the literature","volume":"69","author":"Haas","year":"2011","journal-title":"Neth J Med"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0245","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","article-title":"Radiation recall with anticancer agents","volume":"15","author":"Burris","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0250","first-page":"1094","article-title":"Doxorubicin induced melanonychia","volume":"40","author":"Issaivanan","year":"2003","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0255","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5070\/D365M8X79P","article-title":"Doxorubicin-induced hyperpigmentation","volume":"14","author":"Abbasi","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0260","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1056\/NEJMicm1014268","article-title":"Images in clinical medicine: chemotherapy-induced hyperpigmentation of the tongue","volume":"365","author":"Blaya","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0265","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.1978.03290150070030","article-title":"Urticaria following intravenous doxorubicin administration","volume":"240","author":"Souhami","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0270","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0190-9622(87)70189-3","article-title":"Inflammation of actinic keratoses from systemic chemotherapy","volume":"17","author":"Johnson","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0275","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0268-960X(97)90020-5","article-title":"Anthracyclines in haematology: preclinical studies, toxicity and delivery systems","volume":"11","author":"Richardson","year":"1997","journal-title":"Blood Rev"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0280","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/1078155215580468","article-title":"Bleomycin-induced flagellate erythema in a patient with Hodgkin\u2019s lymphoma\u2014a case report and review of literature","volume":"22","author":"Vennepureddy","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0285","first-page":"807","article-title":"Bleomycin-induced flagellate erythema: a rare and unique drug rash","volume":"63","author":"Changal","year":"2014","journal-title":"West Indian Med J"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0290","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-005-0030-7","article-title":"Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors","volume":"57","author":"Rodriguez-Galindo","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26457","article-title":"Investigating the heterogeneity of alkylating agents\u2019 efficacy and toxicity between sexes: a systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)","volume":"64","author":"Fresneau","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0300","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jdv.13475","article-title":"Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy","volume":"30","author":"Prieto-Torres","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0305","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2010.07.033","article-title":"Dermatopathologic effects of taxane therapy","volume":"65","author":"Plummer","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0310","first-page":"1534","article-title":"Clinical and histopathologic correlation of an eruption secondary to Taxotere","volume":"9","author":"Beer","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488706775246157","article-title":"Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)","volume":"1","author":"Metro","year":"2006","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0320","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0325","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.jaad.2009.12.019","article-title":"Effect of adapalene on cetuximab-induced painful periungual inflammation","volume":"64","author":"Hachisuka","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-91439-8_1","article-title":"Imatinib mesylate","volume":"212","author":"Waller","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0335","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0340","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4143\/crt.2015.017","article-title":"Severe imatinib-associated skin rash in gastrointestinal stromal tumor patients: management and clinical implications","volume":"48","author":"Park","year":"2016","journal-title":"Cancer Res Treat Off J Korean Cancer Assoc"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0345","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2174\/0929867321666141216125528","article-title":"Multi-kinase inhibitors","volume":"22","author":"Garuti","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0350","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/ijms18020461","article-title":"Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Randrup Hansen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0355","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0360","series-title":"Pazopanib versus sunitinib in the treatment of locally advanced and\/or metastatic renal cell carcinoma","author":"ClinicalTrials.gov","year":"2008"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0365","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","article-title":"Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway","volume":"148","author":"Huang","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0370","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0375","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0380","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/13543784.2017.1384813","article-title":"Clinical development of mTor inhibitors for renal cancer","volume":"26","author":"Ghidini","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0385","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4809751","article-title":"A review of mTOR pathway inhibitors in gynecologic cancer","volume":"2017","author":"de Melo","year":"2017","journal-title":"Oxidative Med Cell Longev"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0390","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/0284186X.2014.923583","article-title":"Incidence and risk of rash to mTOR inhibitors in cancer patients\u2014a meta-analysis of randomized controlled trials","volume":"54","author":"Shameem","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0395","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry Jonathan","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0400","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0405","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1159\/000452944","article-title":"Debilitating skin toxicity associated with pembrolizumab therapy in an 81-year-old female with malignant melanoma","volume":"9","author":"Khokhar","year":"2016","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0410","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez Adriana","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0415","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0420","first-page":"79","article-title":"Update on use of aldesleukin for treatment of high-risk metastatic melanoma","volume":"4","author":"Amaria","year":"2015","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0425","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00128071-200001010-00008","article-title":"Denileukin diftitox","volume":"1","author":"Figgitt","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0435","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mjd.2001.117852","article-title":"A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis","volume":"45","author":"Martin","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.006_bb0440","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Target Oncol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X19301828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X19301828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:15:40Z","timestamp":1760033740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X19301828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0738081X19301828"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2019.10.006","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug eruptions associated with tumor therapy: Great imitators","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2019.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}